Abstract
Heart failure is a growing pandemic affecting approximately 6.2 million people in the US and 15 million people worldwide. Given its prevalence, high morbidity and mortality, and financial burden on our healthcare system, establishing strategies focused on improving therapeutic outcomes and prognosis has become a major priority. There have been more major strides in the management of end-stage heart failure patients than ever before. Mechanical circulatory support devices are not only a bridge to transplantation but have become a destination therapy. This review article continues to expand on the importance, necessary tools, and benefits of LVAD shared care and implanting centers on improving patient outcomes, satisfaction, and quality of life. This new approach in patient management can decrease financial costs and increase survival rates which will improve therapies and outlook in end-stage heart failure patients.